Early Immune Modulation by Single-Agent Trastuzumab as a Marker of Trastuzumab Benefit

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0318-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Trastuzumab (Herceptin)

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2011English

Trastuzumab Cardiotoxiciy: The Age-Old Balance of Risk and Benefit

British Journal of Cancer
Cancer ResearchOncology
2016English

Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2008English

Trastuzumab: A Cardiologist’s Perspective

Current Oncology
Oncology
2008English

Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study

Oncologist
Cancer ResearchMedicineOncology
2013English

Current Perspective – Trastuzumab

European Journal of Cancer
Cancer ResearchOncology
2009English

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

Dual HER2 Blockade Versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Oncology
Oncology
2020English

Cardiac Management During Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group

Current Oncology
Oncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy